bioAffinity Technologies Raises $4M in Registered Direct Offering…

Event summary

bioAffinity Technologies closed a $4M registered direct offering of common stock and pre-funded warrants at $6.122 per share.
Concurrent private placement of warrants to purchase up to 980,722 shares at an exercise price of $6.122 per share.
Proceeds to be used for working capital and supporting sales of CyPath® Lung, its noninvasive lung cancer test.
Offering conducted under a shelf registration statement on Form S-3, effective since November 27, 2023.

The big picture

This $4M capital raise reflects bioAffinity's strategic push to scale its noninvasive lung cancer detection technology amid growing demand for early diagnostic solutions. The funding underscores the company's focus on commercializing CyPath® Lung, positioning it within the competitive landscape of diagnostic biotech. The use of Nasdaq's at-the-market rules and a shelf registration streamlines future financing flexibility, aligning with broader trends in healthcare capital markets.

What we're watching

Revenue Growth: How the $4M infusion will accelerate commercialization of CyPath® Lung and drive near-term sales growth.
Market Positioning: Whether bioAffinity can leverage this funding to strengthen its competitive edge in noninvasive lung disease detection.
Execution Risk: The pace at which bioAffinity converts working capital into tangible product advancements and market expansion.